NTM Info & Research (NTMir) is a 501(c)(3) non-profit organization formed on behalf of patients with pulmonary nontuberculous mycobacterial (NTM) disease, bronchiectasis, and other related comorbid diseases for patient support, medical education, and research. NTMir’s mission is to save and improve lives by raising awareness, providing education and a broad support network for patients, and catalyzing research to promote early detection, accelerate the development of improved treatments and improve the quality of life for these patients.
Nordic Bioscience A/S
Nordic Bioscience is a Danish biomarker company headquartered in Herlev, Denmark. Nordic Bioscience is engaged in biomarker development using our unique neoepitope technology. We combine our expertise in biomarker development with preclinical and clinical research. This enables us to develop biomarkers that provide fast and objective decision-making for compound selection and development in clinical trials as well as provide value for patients in a diagnostic setting.
National Jewish Health
National Jewish Health is the leading respiratory hospital in the nation. Founded 125 years ago as a nonprofit hospital, National Jewish Health today is the only facility in the world dedicated exclusively to groundbreaking medical research and treatment of patients with respiratory and complex diseases. Patients and families come to National Jewish Health from around the world to receive cutting-edge, comprehensive, coordinated care. To learn more, visit njhealth.org.
Monaghan Medical Corporation
Monaghan Medical Corporation (MMC), headquartered in Plattsburgh, New York, offers leading aerosol drug delivery devices and respiratory management products including the AeroEclipse® II BAN, AeroChamber® Brand of VHC and the Aerobika® OPEP device exclusively in the United States. MMC focuses on developing cost-efficient, outcome-based solutions for its customers. www.monaghanmed.com
Insmed
Insmed is a global biopharmaceutical company dedicated to the development of treatments for serious and rare diseases. We have more than 700 employees throughout the U.S., Europe, and Japan, and we continue to build our global infrastructure and organizational capabilities. Our five core values—collaboration, accountability, passion, respect, and integrity—set the tone for our culture and guide the actions we take each day. | Insmed Incorporated is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. Insmed is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines as well as cutting-edge drug discovery focused on serving patient communities where the need is greatest. Insmed’s most advanced programs are in pulmonary and inflammatory conditions. Headquartered in Bridgewater, New Jersey, Insmed has offices and research locations throughout the United States, Europe, and Japan. Visit www.Insmed.com to learn more.
Inogen
Inogen, Inc. is a leading global medical technology company offering innovative respiratory products for use in the homecare setting. Inogen supports patient respiratory care by developing, manufacturing, and marketing innovative respiratory therapy devices used to deliver care to patients suffering from chronic respiratory conditions. Inogen partners with patients, prescribers, home medical equipment providers, and distributors to make its respiratory therapy products widely available allowing patients the chance to remain ambulatory while managing the impact of their disease.
ICU Medical
ICU Medical is a global leader offering clinically essential products and solutions that connect patients with caregivers through life-enhancing, innovative technology and services that provide meaningful clinical value. Our robust portfolio features medical delivery systems and consumable products for infusion therapy, emergency medicine, general and regional anesthesia, homecare, neo and ped critical care, oncology, pain management, and respiratory care. We are a dedicated partner delivering leading-edge products across the continuum of care. | ICU Medical is a global leader offering clinically essential products and solutions that connect patients with caregivers through life-enhancing, innovative technology and services that provide meaningful clinical value. Our robust portfolio features medical delivery systems and consumable products for infusion therapy, emergency medicine, general and regional anesthesia, homecare, NICU/PICU, oncology, pain management, and respiratory care. We are a dedicated partner delivering leading-edge products across the continuum of care. | ICU Medical is a global leader offering clinically essential products and solutions that connect patients with caregivers through life-enhancing, innovative technology and services that provide meaningful clinical value. Our robust portfolio features medical delivery systems and consumable products for infusion therapy, emergency medicine, general and regional anesthesia, homecare, NICU/PICU, oncology, pain management, and respiratory care. We are a dedicated partner delivering leading-edge products across the continuum of care.
Hyfe
Hyfe is the global leader in providing continuous, passive cough monitoring as an endpoint for clinical trials and research. Hyfe’s CoughMonitor Suite is a smartwatch-based solution used in numerous regulatory-focused drug development trials, from proof of concept to Phase 3 studies, as an exploratory or primary endpoint across therapeutic areas including refractory chronic cough, bronchiectasis, COPD, and more. Hyfe’s CoughMonitor Suite is a validated, accurate, and fully privacy-preserving solution for continuous cough monitoring. Hyfe’s cough monitoring has been used in over 50 research trials and has resulted in over 20 peer-reviewed publications spanning more than 18 therapeutic indications. Hyfe is also developing an evidence-based digital therapeutic (DTx) solution for cough hypersensitivity, which recently reported over a 40% reduction in cough frequency over 4 weeks. Hyfe’s DTx is already licensed for development as a prescription DTx in Japan, and Hyfe is actively seeking partners to address cough hypersensitivity as a treatable trait of respiratory conditions (e.g., asthma, among others) in other global markets.